{"created":"2023-06-20T13:11:31.567788+00:00","id":735,"links":{},"metadata":{"_buckets":{"deposit":"f8f30b06-9352-4b81-b19e-ad57cd4f727c"},"_deposit":{"created_by":15,"id":"735","owners":[15],"pid":{"revision_id":0,"type":"depid","value":"735"},"status":"published"},"_oai":{"id":"oai:tohoku-mpu.repo.nii.ac.jp:00000735","sets":["3:69"]},"author_link":[],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2017-12","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"64","bibliographicPageEnd":"76","bibliographicPageStart":"65","bibliographic_titles":[{"bibliographic_title":"東北医科薬科大学研究誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Journal of Tohoku Medical and Pharmaceutical University","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Malignant mesothelioma is one of the aggressive cancer that results most commonly from exposure to asbestos. Treatment options of this cancer are limited even in the case of chemotherapy. Moreover, mesothelioma often becomes resistant to pemetrexed and cisplatin, the key drugs for the mesothelioma treatment. Sialic acid binding lectin isolated from rana catesbeiana oocytes（cSBL）shows remarkable anti-tumor effects caused by its ribonuclease activity in mesothelioma cells and exhibits high synergistic effect with pemetrexed. To find more effective combination regimen of cSBL, we examined currently estimated anti-mesothelioma drugs, TNF-related apoptosis-inducing ligand（TRAIL）and EGF receptor-tyrosine kinase inhibitors（erlotinib, gefitinib, and vandetanib）, by using pemetrexed-resistant cell lines, H28-PR and H2452-PR, in vitro. Consequently, the former showed slightly cross-resistance to gefitinib and the latter to cisplatin, cSBL, gefitinib, and vandetanib, respectively. In multiple drugs combination study, pemetrexed＋cSBL and pemetrexed＋cisplatin＋cSBL were higher effective than the other regimens from the aspects of antiproliferative and synergistic effects. Cleavage of Bid and caspase-3 protein which is the sign of apoptosis, and both downregulation of p21 and stabilization of cyclin A which is of cytostatic effects, were detected dependent on the drugs used in the combination treatments. According to these results, we estimated that pemetrexed＋cSBL＋TRAIL combination showed strong synergy by playing the role without any interference and may serve as a rational regimen with the object of anti-proliferative mechanism. In conclusion, our results indicated that cSBL-containing combination treatments show promise for the treatment of malignant mesothelioma.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"東北医科薬科大学","subitem_publisher_language":"ja"}]},"item_10002_rights_15":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0)","subitem_rights_language":"en","subitem_rights_resource":"https://creativecommons.org/licenses/by-nc-nd/3.0/deed.en"}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2432-5724","subitem_source_identifier_type":"PISSN"}]},"item_10002_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"佐藤, 稔之","creatorNameLang":"ja"},{"creatorName":"サトウ, トシユキ","creatorNameLang":"ja-Kana"},{"creatorName":"Satoh, Toshiyuki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"立田, 岳生","creatorNameLang":"ja"},{"creatorName":"タツタ, タケオ","creatorNameLang":"ja-Kana"},{"creatorName":"Tatsuta, Takeo","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"菅原, 栄紀","creatorNameLang":"ja"},{"creatorName":"スガワラ, シゲキ","creatorNameLang":"ja-Kana"},{"creatorName":"Sugawara, Shigeki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"原, 明義","creatorNameLang":"ja"},{"creatorName":"ハラ, アキヨシ","creatorNameLang":"ja-Kana"},{"creatorName":"Hara, Akiyoshi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"細野, 雅祐","creatorNameLang":"ja"},{"creatorName":"ホソノ, マサヒロ","creatorNameLang":"ja-Kana"},{"creatorName":"Hosono, Masahiro","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-12-06"}],"displaytype":"detail","filename":"原著2_佐藤稔之.pdf","filesize":[{"value":"2.7 MB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"新規抗がん剤候補としてのレクザイムを用いた悪性中皮腫細胞に対する多剤併用効果の検討","objectType":"fulltext","url":"https://tohoku-mpu.repo.nii.ac.jp/record/735/files/原著2_佐藤稔之.pdf"},"version_id":"7a7dc8e2-d6e2-477a-a9cb-9b554b1aa53f"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Combination chemotherapy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"drug resistance","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"malignant mesothelioma","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"sialic acid binding lectin","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"新規抗がん剤候補としてのレクザイムを用いた悪性中皮腫細胞に対する多剤併用効果の検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"新規抗がん剤候補としてのレクザイムを用いた悪性中皮腫細胞に対する多剤併用効果の検討","subitem_title_language":"ja"},{"subitem_title":"Combinatorial Treatment Using Leczyme as a New Candidate of Anti-Cancer Drug for Malignant Mesothelioma Cell Lines","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"15","path":["69"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2018-12-06"},"publish_date":"2018-12-06","publish_status":"0","recid":"735","relation_version_is_last":true,"title":["新規抗がん剤候補としてのレクザイムを用いた悪性中皮腫細胞に対する多剤併用効果の検討"],"weko_creator_id":"15","weko_shared_id":-1},"updated":"2024-03-03T23:41:35.118274+00:00"}